Amundi Sells 142,679 Shares of Solventum Corporation $SOLV

by · The Cerbat Gem

Amundi lessened its holdings in Solventum Corporation (NYSE:SOLV – Free Report) by 21.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 526,437 shares of the company’s stock after selling 142,679 shares during the quarter. Amundi’s holdings in Solventum were worth $36,951,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Concurrent Investment Advisors LLC bought a new stake in shares of Solventum in the 1st quarter worth about $216,000. Bessemer Group Inc. grew its holdings in shares of Solventum by 17.1% in the 1st quarter. Bessemer Group Inc. now owns 1,963 shares of the company’s stock worth $150,000 after purchasing an additional 287 shares during the last quarter. Comerica Bank grew its holdings in shares of Solventum by 39.7% in the 1st quarter. Comerica Bank now owns 77,725 shares of the company’s stock worth $5,910,000 after purchasing an additional 22,079 shares during the last quarter. CW Advisors LLC bought a new stake in shares of Solventum in the 1st quarter worth about $312,000. Finally, Raymond James Financial Inc. grew its holdings in shares of Solventum by 12.0% in the 1st quarter. Raymond James Financial Inc. now owns 315,099 shares of the company’s stock worth $23,960,000 after purchasing an additional 33,790 shares during the last quarter.

Solventum Stock Up 0.4%

Shares of NYSE SOLV opened at $72.70 on Monday. The firm’s 50-day simple moving average is $73.53 and its 200 day simple moving average is $72.75. The company has a market cap of $12.61 billion, a price-to-earnings ratio of 33.66, a price-to-earnings-growth ratio of 2.97 and a beta of 0.53. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92.

Solventum (NYSE:SOLV – Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same period in the prior year, the company posted $1.56 EPS. The company’s revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on SOLV shares. Piper Sandler reaffirmed an “overweight” rating and issued a $94.00 target price (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Wells Fargo & Company upped their target price on shares of Solventum from $75.00 to $79.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a research report on Tuesday, July 1st. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Wall Street Zen upgraded shares of Solventum from a “buy” rating to a “strong-buy” rating in a research report on Monday, September 1st. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Solventum presently has a consensus rating of “Hold” and a consensus price target of $85.75.

Get Our Latest Report on Solventum

Solventum Company Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Read More

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).